当前位置: X-MOL 学术Eur. J. Heart Fail. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mega‐trials in heart failure: effects of dilution in examination of new therapies
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2020-03-30 , DOI: 10.1002/ejhf.1780
Beth A. Davison 1 , Koji Takagi 2 , Stefanie Senger 1 , Gary Koch 3 , Marco Metra 4 , Antoine Kimmoun 5 , Alexandre Mebazaa 2 , Adriaan A. Voors 6 , Olav W. Nielsen 7 , Ovidiu Chioncel 8 , Peter S. Pang 9 , Barry H. Greenberg 10 , Aldo P. Maggioni 11 , Alain Cohen-Solal 12 , Georg Ertl 13 , Naoki Sato 14 , John R. Teerlink 15 , Gerasimos Filippatos 16 , Piotr Ponikowski 17 , Etienne Gayat 18 , Christopher Edwards 1 , Gad Cotter 1
Affiliation  

Over the last 30 years, many medicine development programmes in acute and chronic heart failure (HF) with preserved ejection fraction (HFpEF) have failed, in contrast to those in HF with reduced ejection fraction (HFrEF). We explore how the neutral results in larger HF trials may be attributable to chance and/or the dilution of statistical power.

中文翻译:

心力衰竭的大型试验:稀释对新疗法的影响

在过去的30年中,与射血分数降低(HFrEF)的HF相比,许多射血分数保留(HFpEF)的急性和慢性心力衰竭(HF)药物开发计划都失败了。我们探索了大型HF试验中的中性结果如何归因于机会和/或统计功效的稀释。
更新日期:2020-03-30
down
wechat
bug